An observational study in Aortic Valve Disease and Aortic Valve Stenosis, sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd.. Not yet recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-04.
Sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd. (part of MicroPort Scientific Corporation) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.
Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 19th largest by planned enrollment of the 22 observational ones that give a count, is one of 5 that started in 2023, is one of 22 observational ones, reaches primary completion later than 17 of the 50 other live ones, and was the 33rd registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 35–80
Yan'an Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18+
Beijing Balance Medical Technology Co., Ltd · Sites in China
Ages 60–100
Anhui Provincial Cancer Hospital · Sites in China
Ages 18–80 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 89 is below the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 120 across the 47 interventional studies, 490 across the 22 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai MicroPort CardioFlow Medtech Co., Ltd., one of the names counted as MicroPort Scientific Corporation. Under that name alone:
Shanghai MicroPort CardioFlow Medtech Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
MicroPort Scientific Corporation has 9 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07335900RenJi HospitalA Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis | 2026-12-30 |
| NCT07390513Chinese Academy of Medical Sciences, Fuwai HospitalElectrophysiological Outcomes After Transcatheter Aortic Valve Replacement | 2026-12-31 |
| NCT06891079Xijing HospitalVideodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA | 2026-12-31 |
| NCT07035847Chinese Academy of Medical Sciences, Fuwai HospitalTransaxillary TAVR With Solely Echocardiography Guidance | 2026-12-31 |
| NCT07414342Beijing Balance Medical Technology Co., LtdSafety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in Aortic Valve Stenosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an observational study to evaluate the long-term safety and effectiveness of the valve system.
This study is an observational study, for who have joined the VitaFlow® Catheter Aortic Valve System pre-market trial (Protocol No. valve -2014-04) in 4 designated research institutions, and follow-up from 6 to 10 years after the procedure, To evaluate the long-term safety and effectiveness of the valve system.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
This study's planned enrollment of 89 is below the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Browse Aortic Valve Stenosis studies →Shanghai MicroPort CardioFlow Medtech Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
Compared within Aortic Valve Stenosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Valve Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients who have participated in the VitaFlow® transcatheter aortic valve system pre-market trial
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must meet 1, 2, 3, 4 or 1, 5 to be selected:
Patients who are known to have died.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non Interventional long term safety follow up
Device: VitaFlow® Transcatheter Aortic Valve Replacement System
This study is an observational study, for who have joined the VitaFlow® Catheter Aortic Valve System pre-market trial
All cause mortality
rate of all cause mortality
Time frame: 7years after the operation
Cardiac death
rate of Cardiac death
Time frame: 6 years, 7 years, 8 years, 9 years and 10 years after the operation
Stroke
rate of stroke
Time frame: 6 years, 7 years, 8 years, 9 years and 10 years after the operation
valve-related rehospitalization
rate of valve-related rehospitalization
Time frame: 6 years, 7 years, 8 years, 9 years and 10 years after the operation
Serious Adverse Event
rate of Serious Adverse Event
Time frame: 6 years, 7 years, 8 years, 9 years and 10 years after the operation
Blood pressure
Systolic and Diastolic Blood Pressure
Time frame: 6 years, 7 years, 8 years, 9 years and 10 years after the operation
The 12-Item Short Form Health Survey (SF-12)
Scores range from 0 to 100, higher scores are better
Time frame: 6years, 7years, 8 years, 9 years and 10 years after the operation
Mean transvalvular pressure gradient
Transthoracic Echocardiogram test
Time frame: 7years,and 10 years after the operation
Effective orifice area
Transthoracic Echocardiogram test
Time frame: 7years,and 10 years after the operation
Peak velocity
Transthoracic Echocardiogram test
Time frame: 7years,and 10 years after the operation
class of Paravalvular leak
Transthoracic Echocardiogram test
Time frame: 7years,and 10 years after the operation
class of Aortic regurgitation
Transthoracic Echocardiogram test
Time frame: 7years,and 10 years after the operation
New York Heart Association Class for heart function
NYHA class
Time frame: 7years,and 10 years after the operation
Kansas City Cardiomyopathy Questionnaire
Kansas City Cardiomyopathy Questionnaire(score 0-100), higher scores are better
Time frame: 7years,and 10 years after the operation
Natriuretic peptide tests ( NT Pro-BNP or BNP)
blood test
Time frame: 7years,and 10 years after the operation
moderate and severe structural valve deterioration SVD
Transthoracic Echocardiogram test
Time frame: 7years,and 10 years after the operation
bioprosthetic valve failure,BVF
Transthoracic Echocardiogram test
Time frame: 7years,and 10 years after the operation
All cause mortality
rate of all cause mortality
Time frame: 6 years, 8 years, 9 years and 10 years after the operation
Start is estimated for Jul 2023; primary completion for Oct 2025, 27 months later.
Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 27 months is below that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai MicroPort CardioFlow Medtech Co., Ltd. →